Dyne Therapeutics (DYN) Non-Current Deffered Revenue (2019 - 2020)
Dyne Therapeutics (DYN) posted quarterly Non-Current Deffered Revenue of $13000.0 for Q3 2020, down 69.05% quarter-over-quarter from $42000.0 in Q4 2019.
Dyne Therapeutics (DYN) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Dyne Therapeutics (DYN) has reported Non-Current Deffered Revenue for 2 consecutive years, with $13000.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Non-Current Deffered Revenue changed N/A year-over-year to $13000.0; the TTM figure through Sep 2020 stood at $13000.0 (changed N/A YoY), while the FY2019 annual figure was $42000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue declined to $13000.0 in Q3 2020 per DYN's latest filing, from $42000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $42000.0 in Q4 2019 and bottomed at $13000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 13,000.00 |
| Dec 31, 2019 | 42,000.00 |